Prof. YOU Hoi-sze, Joyce

About me

YOU Hoi-sze, Joyce 姚凱詩

PharmD, BCPS (AQ Infectious Diseases)
Professor, School of Pharmacy
Assistant Dean (Student Development), Faculty of Medicine
The Chinese University of Hong Kong

Tel: (852) 3943 6830
Fax:(852) 2603 5295

Personal Details

Prof. Joyce You joined the School of Pharmacy in 1999. She earned her Doctor of Pharmacy (PharmD) degree from the University of Illinois at Chicago (US) and completed her Pharmacy Practice Residency at the University of Michigan (US). Prof. You is a certified Specialist by the Board of Pharmacy Specialties (US) in Pharmacotherapy with Added Qualification in Infectious Diseases.

Prof. You has initiated cost-effectiveness studies in collaboration with researchers from the disciplines of Cardiology, Clinical Pharmacology, Gastroenterology & Hepatology, Haematology, Infectious Diseases, Microbiology, Obstetrics & Gynaecology, Oncology, Orthopedics & Traumatology, Public Health, Psychology, and Psychiatry.

Prof. You had leaded a randomised clinical trial comparing outcomes of pharmacist-managed versus physician-managed anticoagulation clinic. As a result of this project, the first clinical pharmacist-managed anticoagulation clinic in Hong Kong was established at the Prince of Wales Hospital (PWH) in 2002 and now sustained by the staff of Pharmacy Department at PWH.


Research Interests

The focus of Dr. You’s research is the methodology development of pharmacoeconomics and health outcomes research, especially simulation designs using decision tree and Markov models. She works closely with Infectious Diseases and Microbiology physicians on outcome studies of infections caused by multi-drug resistant bacteria and emerging viruses. Much of her work also involves the study of anticoagulation therapy for Chinese patients, including the optimal control of anticoagulation therapy, the cost-effectiveness of the various models of care for patients receiving warfarin, and the role and cost-effectiveness of pharmacogenetic testing for Chinese patients receiving anticoagulation therapy.



  • Bachelor of Pharmacy Programme
    • PHAR1440 Clinical Microbiology and Infection Control
    • PHAR3413 Pharmacology & Therapeutics II
    • PHAR3415 Pharmacology & Therapeutics IV
    • PHAR4303 Clinical Pharmacy Clerkship: Infectious Diseases
    • PHAR4911 Research Project I
    • PHAR4912 Research Project II
  • MPhil & PhD in Pharmacy
    • PHAR5130 Overview of Drug Development
  • Master of Clinical Pharmacy Programme
    • PHAR 5882 Pharmacotherapy: Infectious Diseases
    • PHAR5924 Graduation Project II


Recent Publications

  1. Fekadu G, Jiang X, Yao J, You JH. Cost-effectiveness of video-observed therapy for ambulatory management of active tuberculosis during COVID-19 pandemic in a high-income country. International Journal of Infectious Diseases (accepted for publication on 14 October 2021).
  2. Fekadu G, Chow DY, You JHS. The pharmacotherapeutic management of pulmonary tuberculosis: an update on the state-of-the-art. Expert Opinion on Pharmacotherapy. 2021 Aug 21:1-10. doi: 10.1080/14656566.2021.1967930. Epub ahead of print.
  3. Fekadu G, Yao J, You JHS. A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries. Expert Review of Pharmacoeconomics & Outcomes Research. 2021 Oct;21(5):897-910. doi: 10.1080/14737167.2021.1925111.
  4. Jiang X, Yao J, You JH. Cost-effectiveness of a Telemonitoring Program for Patients With Heart Failure During the COVID-19 Pandemic in Hong Kong: Model Development and Data Analysis. Journal of Medical Internet Research. 2021 Mar 3;23(3):e26516. doi: 10.2196/26516.
  5. You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, Au JSK. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis. PLOS One. 2021 Mar 1;16(3):e0247860. doi: 10.1371/journal.pone.0247860. 
  6. Yao J, Jiang X, You JHS. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn’s disease patients: A Cost-effectiveness analysis. Journal of Gastroenterology and Hepatology. 2021 Sep;36(9):2397-2407. doi: 10.1111/jgh.15373.
  7. You JHS. Impact of COVID-19 infection control measures on influenza-related outcomes in Hong Kong. Pathogens and Global Health. 2021 Mar;115(2):93-99. doi: 10.1080/20477724.2020.1857492.
  8. Jiang X, Yao J, You JH. Telemonitoring Versus Usual Care for Elderly Patients With Heart Failure Discharged From the Hospital in the United States: Cost-Effectiveness Analysis. JMIR Mhealth Uhealth. 2020 Jul 6;8(7):e17846. doi: 10.2196/17846.
  9. Yao J, Jiang X, You JHS. A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: From immunosuppressive to anti-TNF therapy. Inflammatory Bowel Diseases. 2021 Jan 19;27(2):275-282. doi: 10.1093/ibd/izaa073.
  10. You JHS, Jiang X, Lee WH, Chan PKS, Ng SC. Cost‐effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology. 2020 Sep;35(9):1515-1523. doi: 10.1111/jgh.15002.

More Publications

Supplementary Information


Teacher of the Year Award 2005/06, School of Pharmacy, Faculty of Medicine, CUHK

Teacher of the Year Award 2010/11, School of Pharmacy, Faculty of Medicine, CUHK

Comments are closed